



RECEIPT
PATENT

RECEIVED

AUG 13 2001

TECH CENTER 1600/2900

Applicant: Berinstein et al.

Examiner: Unassigned

Serial No.: 09/693,754

Group Art Unit: 1653

Filed: October 20, 2000

Docket: 13115

For: Method of Inducing and/or Enhancing
an Immune Response to Tumor Antigens

Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, NY 10022

Dated: February 2, 2001

Assistant Commissioner for Patents
Washington, DC 20231

REQUEST FOR CORRECTED FILING RECEIPT

SIR or MADAM:

Attached is a copy of the Official Filing Receipt received from the United States Patent and Trademark Office for the above-identified application. Applicants have noted the following errors contained therein and respectfully request a corrected Filing Receipt.

The continuing data should read:

"This application claims benefit of 60/160,879 filed 10/22/99 and 60/223,325 filed 08/07/00".

If there are any questions or comments relating to this request, the Examiner is respectfully invited to contact Applicants' attorney at the telephone number set forth below.

Certificate of Mailing Under 37.C.F.R. 1.8
I hereby declare that this correspondence is being deposited with
the United States Postal Service as first class mail in an envelope
addressed to: Assistant Commissioner of Patents, Washington, D.C.
Date 2/2/01 Name Franklin S. Abrams
20231

Respectfully submitted,

Franklin S. Abrams
Franklin S. Abrams
Registration No.: 43,457
Attorney for Applicant(s)

Kalow & Springut LLP
Telephone No. (212) 813-1600



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/693,754	10/20/2000	1653	710	13115	11	19	1

Kalow & Springut LLP
488 Madison Avenue 19th Floor
New York, NY 10022



FILING RECEIPT



OC000000005625235

Date Mailed: 12/18/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Neil Berinstein, Residence Not Provided;
James Tartaglia, Residence Not Provided;
Philippe Moingeon, Residence Not Provided;
Brian Barber, Residence Not Provided;

RECEIVED

AUG 13 2001

TECH CENTER 1600/2900

Continuing Data as Claimed by Applicant

This application claims benefit of 60/160,879 Filed 10/22/99 and 60/223,325 filed 08/07/00.
Foreign Applications

December 20, 2000
Fwd. Filing Receipt
01/18/2001
J.F.

If Required, Foreign Filing License Granted 12/16/2000

Title

Method of inducing and/or enhancing an immune response to tumor antigens

Preliminary Class

424

Data entry by : DOUGLAS, BRIDGETTE

Team : OIPE

Date: 12/18/2000



LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

#5



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



Bib Data Sheet

FILE COPY

CONFIRMATION NO. 7885

SERIAL NUMBER 09/693,754	FILING DATE 10/20/2000 RULE	CLASS 424	GROUP ART UNIT 1632	ATTORNEY DOCKET NO. 13115
------------------------------------	---	---------------------	-------------------------------	-------------------------------------

APPLICANTS

Neil Berinstein, Toronto, CANADA;
James Tartaglia, Schenectady, NY;
Philippe Moingeon, Pommiers, FRANCE;
Brian Barber, Mississauga, CANADA;

RECEIVED

AUG 13 2001

TECH CENTER 1600/2900

**** CONTINUING DATA *******

THIS APPLN CLAIMS BENEFIT OF 60/160,879 10/22/1999
AND CLAIMS BENEFIT OF 60/223,325 08/07/2000

**** FOREIGN APPLICATIONS *********IF REQUIRED, FOREIGN FILING LICENSE GRANTED****** 12/16/2000**

Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY CANADA	SHEETS DRAWING 11	TOTAL CLAIMS 19	INDEPENDENT CLAIMS 1
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged	Examiner's Signature	Initials		

ADDRESS

Kalow & Springut LLP
488 Madison Avenue 19th Floor
New York, NY 10022

TITLE

Method of inducing and/or enhancing an immune response to tumor antigens

FILING FEE RECEIVED 840	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit
-----------------------------------	---	---